Interview with Philippe Baudier, Managing Director, S.M.B. Laboratories
Mr Baudier, what inspired you when you joined the company back in 1978 and what are your main goals today? Prior to joining SMB Laboratories, I worked in a publishing…
Address: 26-28, rue de la Pastorale1080 – Brussels – Belgium
Tel: +32.2.411.48.28
S.M.B. is a Belgian based pharmaceutical company with global ambitions. Its objective is to become a leading European player in the field of oral and pulmonary drug delivery systems by being an innovative actor in the pharmaceutical industry.
Thanks to the success of its R&D Department, S.M.B. has become internationally recognized in the field of human health care in various high-tech areas such as Micropellets (microgranules for once daily administration), Lidose® (semi-solid lipidic matrix in hard capsule formulation), Divule® (high gloss gelatine coated tabs), DPI (Dry Powder Inhaler) and Effervescent Tablets design and large scale production.
Together with its exclusive partners, S.M.B. Technology S.A. (Contract Manufacturing) and GALEPHAR M/F (Contract R&D), Laboratoires SMB’s activity embraces a large spectrum of competences in initial R&D, continuous R&D, Clinical Trials, Analytics, production, Regulatory Affairs and Marketing, supporting a pipeline of in-house formulations.
S.M.B. proposes a balanced portfolio of products mainly in:
Respiratory tract
Cardiovascular system
Pain management
OTC
Mr Baudier, what inspired you when you joined the company back in 1978 and what are your main goals today? Prior to joining SMB Laboratories, I worked in a publishing…
PharmaBoardroom was delighted to attend DIA Europe 2024 in Brussels earlier this month, bringing together a veritable who’s-who of the European and global regulatory community. The politicians, regulators, payers, patient…
Belgium, one of Europe’s most important countries for biopharmaceutical production and R&D, assumed presidency of the Council of the European Union on the first of January. As part of its…
A new piece in the January 2023 edition of DIA’s Global Forum magazine lays out how a new coalition aims to transform the landscape for rare disease treatments in Europe…
UCB has been undergoing a far-reaching digital business transformation, integrating novel approaches across its R&D organisation, including Computer-Aided Drug Design (CADD) and AI, while striving to maintain a patient-centric focus.…
Pfizer’s David Isom and Monica Mihedji, writing in the November 2023 edition of the DIA’s Global Forum magazine, examine how the European Medicines Agency is attempting to integrate the use…
Encircled by heavyweight life sciences powerhouses of the likes of Germany, France and Switzerland, plucky Belgium nonetheless continues to astonish and project considerable influence when it comes to its abilities…
The European Coalition for Access to Comprehensive Genomic Profiling (ECGP) is a new initiative made up of industry association the European Confederation of Pharmaceutical Entrepreneurs (EUCOPE), molecular diagnostics firms Exact…
Janssen has the lofty aim of reaching USD 60bn dollars in sales by 2025, an 8bn increase on the 2021 figure, despite some high-profile losses of exclusivity and the spin-off…
There have been both ups and downs in AbbVie’s recent history. After proving its staying power with the celebration of its 10-year anniversary as an independent company spun off from…
Representatives of Belgian associations for innovative pharma, generics and biosimilars, medtech, OTC, biotech, hospitals, and medical professionals share their key agenda priorities. These include where they feel that change is…
Germany and Belgium have long held an important trading relationship, says Margit Kunz of AHK Debelux, the German chamber of commerce in Belgium and Luxembourg. She outlines some of the…
Perhaps to the surprise of many, Belgium is the world’s second-largest producer of vaccines, behind only the US, and – capitalising on its years of experience in the field –…
See our Cookie Privacy Policy Here
